首页 工具
登录
Carboplatin

Carboplatin

产品编号 T1058   CAS 41575-94-4
别名: 卡铂, JM-8, CBDCA, NSC 241240

Carboplatin 是一种具有抗肿瘤活性的顺铂衍生物。它是一种DNA 合成抑制剂,可与 DNA 结合,抑制复制和转录并诱导细胞死亡。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
Carboplatin, CAS 41575-94-4
我们的产品含有多种规格,如需了解具体的规格以及价格信息,请联系我们咨询订购,对于大额的订购,我们还有额外的优惠!
产品咨询
产品目录号及名称: Carboplatin (T1058)
点击图片重新获取验证码
纯度: 98%
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
产品描述 Carboplatin is an organoplatinum compound that possesses antineoplastic activity.
体外活性 腹腔注射60 mg/kg Carboplatin,其单独作用于A2780移植瘤,处理第6天,相对肿瘤体积为8.4,对照组为11.9,且处理第6天,T/C为67%,显示Carboplatin具有适度的抗肿瘤效果.
体内活性 Carboplatin具有抑制细胞增殖的作用,作用于包括A2780,SKOV3和 IGROV-1细胞的一组人类卵巢癌细胞系,IC50分别为6.1 μM,12.4 μM 和2.2 μM。
激酶实验 Radioligand binding studies on human AT1 receptors: A radioligand binding assay is performed by using human AT1 receptor-coated microplates containing 4.4 to 6.2 fmol of receptors/well (10 μg of membrane protein/well). Membrane-coated wells are incubated with 45 μL of assay buffer (50 mM Tris-HCl, 5 mM MgCl2, 1 mM EDTA, and 0.005% CHAPS, pH 7.4) containing various concentrations of Azilsartan at room temperature. After 90 minutes, 5 μL of 125I-Sar1-Ile8-AII (final concentration 0.6 nM) dissolved in assay buffer is added to the wells, and the plate is incubated for 5 hours. In each step, the plate is briefly and gently shaken on a plate shaker. In washout experiments, the membranes are incubated with Azilsartan for 90 minutes, then immediately washed twice with 200 μL/well of assay buffer to remove unbound compounds, and further incubated for 5 hours with 125I-Sar1-Ile8-AII. Membrane-bound radioactivity is counted using a TopCount Microplate Scintillation and Luminescence Counter. In the experiments to estimate the dissociation rate of Azilsartan from AT1 receptors, membranes are incubated for 90 minutes with Azilsartan at a concentration of 30 nM for Azilsartan. Azilsartan inhibits the specific binding of 125I-Sar1-Ile8-AII to human AT1 by approximately 90%. The membranes are then immediately washed twice with 200 μL/well of assay buffer and further incubated with 125I-Sar1-Ile8-AII for 240 minutes. Membrane-bound radioactivity is counted using the TopCount Microplate Scintillation and Luminescence Counterat 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, or 240 minutes. Nonspecific binding of 125I-Sar1-Ile8-AII is estimated in the presence of 10 μM unlabeled AII. Unlabeled AII is added again after washout for the washout experiment. Specific binding is defined as total binding minus nonspecific binding.
细胞实验 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet. (Only for Reference)
别名 卡铂, JM-8, CBDCA, NSC 241240
分子量 371.25
分子式 C6H12N2O4Pt
CAS No. 41575-94-4

存储

 | Powder: -20°C for 3 years | In solvent: -80°C for 2 years

溶解度

DMF: 1 mg/mL (2.69 mM), Need ultrasonic

( < 1 mg/mL refers to the product slightly soluble or insoluble )

参考文献

1. Banerji U, et al. Cancer Chemother Pharmacol. 2008, 62(5), 769-778. 2. Fiebiger W, et al. Clin Transl Oncol. 2011, 13(1), 43-49. 3. Clark CC, et al. Mol Cancer Ther, 2012, doi: 10.1158/1535-7163. MCT-11-0597. 4. Wang H, et al. Clin Cancer Res. 2004, 10(5), 1633-1644. 5. Liu H, et al. Anticancer Res. 2011, 31(9), 2713-2722. 6. Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8(1):116. 7. Liu L, Liu S, Deng P, et al. Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma[J]. Cancer Research.

文献引用

1. Liu L, Liu S, Deng P, et al. Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma. Cancer Research. 2021 Mar 1;81(5):1413-1425. doi: 10.1158/0008-5472.CAN-20-2125. Epub 2021 Jan 5. 2. Liu L, Liu S, Deng P, et al. Targeting the IRAK1–S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma. Cancer Research. 2021, 81(5): 1413-1425. 3. Bi G, Liang J, Zhao M, et al. MiR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma by targeting CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways. Molecular Therapy-Nucleic Acids. 2022 4. Zhu H, Rao Z, Yuan S, et al. One therapeutic approach for triple-negative breast cancer: Checkpoint kinase 1 inhibitor AZD7762 combination with neoadjuvant carboplatin. European Journal of Pharmacology. 2021: 174366.

相关化合物库

该产品包含在如下化合物库中:
抗癌临床化合物库 儿童药物库 毒性化合物库 ReFRAME 相关化合物库 造血毒性小分子库 抗肺癌化合物库 抗癌化合物库 临床前化合物库 肝脏毒性化合物库 人代谢物化合物库

相关产品

具有相同靶点的化合物
KCC-07 Tretazicar N-Nitroso-N-methylurea Carmustine Lomustine Altretamine Temozolomide Carboplatin

剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

bottom

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

Carboplatin 41575-94-4 Autophagy Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA Alkylator/Crosslinker DNA/RNA Synthesis inhibit 卡铂 JM-8 NSC-241240 Inhibitor CBDCA NSC241240 NSC 241240 inhibitor

 

陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼